MammaPrint Genomic Test Helps Early Stage Cancer Patients Safely Avoid Chemo, Agendia’s CMO Says

MammaPrint Genomic Test Helps Early Stage Cancer Patients Safely Avoid Chemo, Agendia’s CMO Says
A genomic test, evaluated in several clinical trials and approved for use in the U.S. and Europe, can effectively tell early stage breast cancer patients what is their risk of cancer returning. The test, called MammaPrint 70-gene Breast Cancer recurrence assay, was developed by Agendia to give patients’ unambiguous low- and high-risk results. The test analyzes the activity of

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *